Ben Samelson-Jones: Do Gene Variants Drive PK Differences in FIX-Fusion and N9-GP Therapies?
Ben Samelson-Jones, Associate Director of Clinical In Vivo Gene Therapy at Children’s Hospital of Philadelphia and Assistant Professor of Pediatrics at University of Pennsylvania School of Medicine, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in JTH, adding:
“As hemophilia treatments become more sophisticated, understanding the role of the dysfunctional F9 variant becomes more important.”
Title: Factor IX gene variants may influence the pharmacokinetic profile of patients with hemophilia B treated with Factor IX-fusion protein or N9-GP extended half-life Factor IX concentrates
Authors: Davide Matino, Zainab Al-Housni, Benjamin Samelson-Jones, Pierre Chelle, Giancarlo Castaman, Jerome Teitel, Shannon Jackson, David Lillicrap, Arun Keepanasseril, Anthony Chan, Kyumin Lee, Andrea Edginton, Alfonso Iorio
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 23, 2026, 13:58The New B12 Diagnostic Algorithm: From Serum Cobalamin to Functional Deficiency
-
Sep 23, 2026, 13:56Noha Soror: Preparing for Hematology and Medical Oncology Board Certification
-
Sep 23, 2026, 13:46Ugochi Ogu: What Can Platelet Proteomics Reveal about Pain and Neurocognitive Vulnerability in Sickle Cell Disease?
-
Sep 23, 2026, 13:42Melissa Hollo: Connecting Obesity and Anemia for Earlier Maternal Risk Intervention
-
Sep 23, 2026, 13:16Beverley Hunt: Advances in Haemostatic Management of Postpartum Haemorrhage
-
Sep 23, 2026, 13:13Ioanna Mela: Recruiting a Research Associate on DNA nanotechnology
-
Sep 23, 2026, 12:57Shelly Reed: Advocating for HTCs and CDC Funding with the Hemophilia Federation of America
-
Sep 23, 2026, 12:51Domenico Girelli: How Verona Hospital Transformed ED Anemia Care with Patient Blood Management
-
Sep 23, 2026, 12:45Lina Camacho-Arteaga: ENTIS Study Uncovers Safety Data on Early Pregnancy Exposure to Direct Oral Anticoagulants